Working to improve pipeline efficiency using genomics
Although the Food and Drug Administration approved a record number of novel therapeutics in 2020, only one drug out of 10 (about 10%) that enters clinical trials is ultimately approved by the FDA. That is a problem, and a costly one at that.
Developing a safe and efficacious drug is quite challenging, as evidenced by a Biostatistics study, which found that 2015’s total revenue from the entire pharmaceutical industry was $1.2 trillion, and $150 billion was spent on R&D. The sobering statistic is that approximately $112 billion of that R&D spent in 2015 (nearly 75%) can be directly attributed to failed clinical trials.
This website stores cookies on your computer. Some of these cookies enable this website to function and some of these cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookie Policy and Privacy Policy.